OBJECTIVE: There is some evidence that use of hormonal contraceptives, particularly the more androgenic formulations, can alter a woman's glucose tolerance. We examined the association between hormonal contraceptive use, categorized by the androgenicity of the progestin component, and risk of gestational diabetes mellitus (GDM) in a nested case-control study. RESEARCH DESIGN AND METHODS: Case (n = 356) and control (n = 368) subjects were selected from a multiethnic cohort of 14,235 women who delivered a singleton live birth between 1 January 1996 and 30 June 1998, who were screened for GDM at 24-28 gestational weeks, and who were members of Kaiser Permanente for at least 5 years before pregnancy. GDM was defined using the National Diabetes Data Group plasma glucose cutoffs. Information concerning hormonal contraceptive use during the 5 years before pregnancy was obtained from medical charts and some pharmacy data. RESULTS: There was a suggestion that compared with no hormonal contraceptive use, use of a low-androgen hormonal contraceptive before pregnancy was associated with a slight reduction in risk of GDM (odds ratio 0.84 [95% CI 0.58-1.22]), whereas use of a high-androgen hormonal contraceptive was associated with a modest increase in GDM risk (1.43 [0.92-2.22]). CONCLUSIONS: The effects of hormonal contraceptive use on GDM risk may vary by the androgenicity of the progestin component.
OBJECTIVE: There is some evidence that use of hormonal contraceptives, particularly the more androgenic formulations, can alter a woman's glucose tolerance. We examined the association between hormonal contraceptive use, categorized by the androgenicity of the progestin component, and risk of gestational diabetes mellitus (GDM) in a nested case-control study. RESEARCH DESIGN AND METHODS: Case (n = 356) and control (n = 368) subjects were selected from a multiethnic cohort of 14,235 women who delivered a singleton live birth between 1 January 1996 and 30 June 1998, who were screened for GDM at 24-28 gestational weeks, and who were members of Kaiser Permanente for at least 5 years before pregnancy. GDM was defined using the National Diabetes Data Group plasma glucose cutoffs. Information concerning hormonal contraceptive use during the 5 years before pregnancy was obtained from medical charts and some pharmacy data. RESULTS: There was a suggestion that compared with no hormonal contraceptive use, use of a low-androgen hormonal contraceptive before pregnancy was associated with a slight reduction in risk of GDM (odds ratio 0.84 [95% CI 0.58-1.22]), whereas use of a high-androgen hormonal contraceptive was associated with a modest increase in GDM risk (1.43 [0.92-2.22]). CONCLUSIONS: The effects of hormonal contraceptive use on GDM risk may vary by the androgenicity of the progestin component.
Authors: E T Jensen; J L Daniels; T Stürmer; W R Robinson; C J Williams; D Moster; P B Juliusson; K Vejrup; P Magnus; M P Longnecker Journal: Int J Obes (Lond) Date: 2014-07-02 Impact factor: 5.095
Authors: Elizabeth E Hatch; Kristen A Hahn; Ellen M Mikkelsen; Anders H Riis; Henrik Toft Sorensen; Kenneth J Rothman; Lauren A Wise Journal: Eur J Epidemiol Date: 2015-06-16 Impact factor: 8.082
Authors: Monique M Hedderson; Michelle A Williams; Victoria L Holt; Noel S Weiss; Assiamira Ferrara Journal: Am J Obstet Gynecol Date: 2008-02-20 Impact factor: 8.661
Authors: Khalid Al-Rubeaan; Hamad A Al-Manaa; Tawfik A Khoja; Amira M Youssef; Ahmad H Al-Sharqawi; Khalid Siddiqui; Najlaa A Ahmad Journal: BMJ Open Date: 2014-08-19 Impact factor: 2.692